[1] Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J (Engl),2021,134(7):783-791. [2] Wu S, Fan K, Yang Q, et al. Smart nanoparticles and microbeads for interventional embolization therapy of liver cancer: state of the art[J]. J Nanobiotechnology,2023,21(1):42. [3] Shindoh J, Kawamura Y, Kobayashi Y, et al. Prognostic Impact of Surgical Intervention After Lenvatinib Treatment for Advanced Hepatocellular Carcinoma[J]. Ann Surg Oncol,2021,28(12):7663-7672. [4] Wang F, Numata K, Takeda A, et al. Optimal application of stereotactic body radiotherapy and radiofrequency ablation treatment for different multifocal hepatocellular carcinoma lesions in patients with Barcelona Clinic Liver Cancer stage A4-B1: a pilot study[J]. BMC Cancer,2021,21(1):1169. [5] Liu J, Liang Y, Ouyang J, et al. Analysis of risk factors and model establishment of recurrence after endometrial polypectomy[J]. Ann Palliat Med,2021,10(11):11628-11634. [6] 赵思任, 张建斌, 张吉论, 等. 创伤性颅脑损伤患者去骨瓣术后脑积水风险列线图模型构建及其价值评估[J]. 创伤外科杂志,2022,24(4):259-264. [7] Ye JZ, Mai RY, Guo WX, et al. Nomogram for prediction of the international study Group of Liver Surgery (ISGLS) grade B/C Posthepatectomy liver failure in HBV-related hepatocellular carcinoma patients: an external validation and prospective application study[J]. BMC Cancer,2020,20(1):1036. [8] He T, Fong JN, Moore LW, et al. An imageomics and multi-network based deep learning model for risk assessment of liver transplantation for hepatocellular cancer[J]. Comput Med Imaging Graph,2021,12(89):101894. [9] 中华人民共和国卫生和计划生育委员会医政医管局. 原发性肝癌诊疗规范(2017年版)[J]. 中华消化外科杂志,2017,16(7):1419-1431. [10] 王建华, 周康荣. 肝癌综合性介入治疗规范化方案(草案)[J]. 现代实用医学,2003,21(1):62-64. [11] Romano F, Chiarelli M, Garancini M, et al. Rethinking the Barcelona clinic liver cancer guidelines: Intermediate stage and Child-Pugh B patients are suitable for surgery[J]? World J Gastroenterol,2021,27(21):2784-2794. [12] Hack SP, Spahn J, Chen M, et al. IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation[J]. Future Oncol,2020,16(15):975-989. [13] Qin S, Li Q, Gu S, et al. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet Gastroenterol Hepatol,2021,6(7):559-568. [14] 王爽, 杨元磊, 孙韬, 等. 自拟解毒疏肝组方治疗肝胆湿热型原发性肝癌介入术后综合症的疗效及预后因素分析[J]. 四川中医,2021,39.(12):127-132. [15] 梅宝富, 邓志锋, 郑兰, 等. γ-谷氨酰转肽酶和血小板比值对肝癌介入术后急性肝功能恶化的预测作用[J]. 肝脏,2021,26(2):175-178. [16] Yuan M, Chen TY, Chen XR, et al. Identification of predictive factors for post-transarterial chemoembolization liver failure in hepatocellular carcinoma patients: A retrospective study[J]. World J Clin Cases,2022,10(24):8535-8546. [17] Grgurevic I, Trkulja V, Bozin T, et al. Infection as a predictor of mortality in decompensated liver cirrhosis: exploring the relationship to severity of liver failure[J]. Eur J Gastroenterol Hepatol,2020,32(11):1458-1465. [18] Watanabe Y, Osaki A, Waguri N, et al. Prognostic study of acute-on-chronic liver failure patients: Usefulness of the fibrosis-4 index[J]. Medicine (Baltimore),2022,101(44):e31328. [19] Shi JY, Sun LY, Quan B, et al. A novel online calculator based on noninvasive markers (ALBI and APRI) for predicting post-hepatectomy liver failure in patients with hepatocellular carcinoma[J]. Clin Res Hepatol Gastroenterol,2021,45(4):101534. |